secwatch.observer — SEC 8-K summary
======================================

Issuer:     HYPERION DEFI, INC. (HYPD)
CIK:        0001682639
Form:       8-K
Filed at:   2021-11-10T23:59:59+00:00
Accession:  0001104659-21-136957
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eyenovia reports Q3 net loss $5.6M; Chairman Eshelman to step down
------------------------------------------------------------------

- Net loss of $5.6M ($0.21 per share) vs $5.1M ($0.23) in Q3 2020; R&D $3.5M, G&A $2.4M.
- Cash $21.4M at Sept 30; expects to fund MydCombi resubmission, MicroLine Phase 3, and manufacturing.
- First patient enrolled in VISION-2 Phase 3 presbyopia trial; topline data expected mid-2022.
- FDA issued Complete Response Letter reclassifying MydCombi as drug-device combo; expedited resubmission planned early 2022.
- Chairman Fred Eshelman to resign by end of 2021; not due to disagreement; Board search to follow.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1682639/000110465921136957/0001104659-21-136957-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1682639/000110465921136957/tm2132498d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-21-136957

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer